Barclays PLC Bluebird Bio, Inc. Call Options Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 12, 2020	BUY	$34.44 - $43.75 $216,972 - $275,625	6,300 Added 1575.0%	6,700 $361,000
Q4 2019 Feb 10, 2020	BUY	$46.96 - $61.67 $4,696 - $6,167	100 Added 33.33%	400 $35,000
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $11,894 - $18,620	-200 Reduced 40.0%	300 $28,000
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $15,168 - $21,042	200 Added 66.67%	500 $64,000
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $6,444 - $10,411	-100 Reduced 25.0%	300 $47,000
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $41,370 - $65,282	-700 Reduced 63.64%	400 $40,000
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $6.94 Million - $9.18 Million	-78,100 Reduced 98.61%	1,100 $161,000
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $7.74 Million - $9.91 Million	77,700 Added 5180.0%	79,200 $12.4 Million
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $529,000 - $754,700	-5,000 Reduced 76.92%	1,500 $256,000
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $227,500 - $365,959	2,800 Added 75.68%	6,500 $1.16 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $213,638 - $338,254	3,700	3,700 $508,000

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $677M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.